Know Cancer

or
forgot password

Phase 3 Study of Etoposide, Cisplatin, and Radiotherapy Versus Paclitaxel, Carboplatin and Radiotherapy in Patients With Unresectable Locally Advanced, Stage III Non-Small Cell Lung Cancer


Phase 2/Phase 3
18 Years
75 Years
Not Enrolling
Both
Non-Small Cell Lung Cancer

Thank you

Trial Information

Phase 3 Study of Etoposide, Cisplatin, and Radiotherapy Versus Paclitaxel, Carboplatin and Radiotherapy in Patients With Unresectable Locally Advanced, Stage III Non-Small Cell Lung Cancer


Inclusion Criteria:



1. Inoperable stage IIIA/IIIB NSCLC proved by pathology or cytology

2. Age 18 to 75, ECOG ≤ 2, lose weight <10% during 6 months

3. No serious diseases of important organs

4. Chest CT in recently 4 weeks

5. No other tumor disease except stage I cervical cancer or cutaneous basal cell
carcinoma

6. Sign consent

7. Measurable lesion

Exclusion Criteria:

1. Pretreatment radiotherapy or chemotherapy

2. Pregnant or lactation woman

3. Serious diseases (include uncontrolled diabetes and infection) of important organs

4. Psychopath

5. Join in other clinical trial

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall Survival

Outcome Time Frame:

2 years

Safety Issue:

No

Principal Investigator

luhua Wang, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Department of Radiation Oncology, Cancer Hospital & Institution, CAMS & PUMC

Authority:

China:Chinese Academy of Medical Sciences

Study ID:

2006BAI02A02[1]-03

NCT ID:

NCT01494558

Start Date:

May 2007

Completion Date:

August 2011

Related Keywords:

  • Non-Small Cell Lung Cancer
  • Overall survival
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location